Xcout IntelApollomics Inc. competitors & alternatives
The 12 closest competitors and alternatives to Apollomics Inc. among biotech companies — ranked by similarity to what Apollomics Inc. actually does, not by market-cap band.
Subscribe to see Apollomics Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Apollomics Inc.
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Apollomics Inc. at a glance
Apollomics Inc. is a biotech company headquartered in Foster City, United States, founded in 2016. It is publicly listed (APLM) with a market capitalisation of $47.2M. Xcout tracks 18 named people at Apollomics Inc., including Hung-Wen Chen (Chief Executive Officer & Chairman of the Board).
Apollomics Inc. leadership
- Hung-Wen ChenChief Executive Officer & Chairman of the Board
- Yi-Kuei ChenDirector & Chief Operating Officer
- K. H. LinChief Financial Officer
- Hung-Wen (Howard) ChenExecutive Officer
- Peter LinExecutive Officer
- Yi-Kuei (Alex) ChenExecutive Officer
12 more named people on record for Apollomics Inc., with roles, board committees and tenure — see the full roster →
Top 12 Apollomics Inc. competitors
Ranked by semantic similarity — how close each company is to Apollomics Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Beijing Avistone Biotechnology Co., Ltd. is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of oncology treatments. The company develops innovative targeted drugs, such as plemitinib and abelmetinib, to serve cancer patients globally.
Similar biotech company
TYK Medicines, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, obtaining, advancing, and bringing to market innovative treatments for significant unmet needs in oncology. The company's primary drug candidate, TY-9591, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It is being developed to treat non-small cell lung cancer (NSCLC) with EGFR mutations that has metastasized to the brain, as well as locally advanced or metastatic NSCLC characterized by the EGFR L858R mutation. Beyond its lead candidate, TYK Medicines maintains a diverse pipeline of other investigational therapies. These include TY-302, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor designed for solid tumors such as breast and prostate cancer. Another compound, TY-2136b, is an oral ROS proto-oncogene 1/neurotrophic tyrosine receptor kinase inhibitor also aimed at solid tumors. The company is advancing TY-2699a, a selective CDK7 inhibitor, and TY-0540, a selective CDK2/4/6 inhibitor, both targeting advanced or metastatic solid malignancies. Further, the pipeline features TY-4028, an oral exon 20 insertion tyrosine kinase inhibitor (TKI) specifically addressing locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 or HER2 exon 20 insertions. TY-1091 is a potent and selective rearranged during transfection proto-oncogene (RET) inhibitor, under development for advanced NSCLC with RET gene fusion, advanced medullary thyroid cancer with RET gene mutation, and other solid tumors presenting RET gene alterations. Other promising programs include TY-1054, an oral yes-associated protein-transcriptional enhanced associate domain inhibitor for various cancers; TY-1210, a selective CDK2 inhibitor for solid tumors; TY-0609, a selective CDK4 inhibitor also for cancer therapy; and TY-3200, an innovative EGFR degrader. Established in 2017, the enterprise operates from its main office located in Huzhou, China.
Biotechnology
Apeiron Therapeutics is a clinical-stage biopharmaceutical and precision oncology company focused on developing biomarker-driven therapeutics for cancer.
Similar biotech company
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Similar biotech company
Aptose Biosciences Inc. is a clinical-stage biotechnology company that develops small molecule cancer therapeutics, focusing on precision medicines for hematologic malignancies. The company's product pipeline features investigational drug candidates such as tuspetinib and luxeptinib, which are designed to treat conditions like acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and B-cell malignancies.
Similar biotech company
Alphamab Oncology operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, production, and market introduction of biological therapies for cancer. Its comprehensive product pipeline includes several key assets: KN046, a bispecific monoclonal antibody (BsAb) designed to inhibit immune checkpoints, is currently in pivotal Phase III clinical trials, targeting the clinically validated PD-L1 and CTLA-4 pathways. Another significant candidate is KN026, a cutting-edge anti-human epidermal growth factor receptor 2 (HER2) BsAb. This therapy is undergoing Phase II clinical studies for HER2-positive breast cancers (with Phase I/II trials specifically for heavily pre-treated cases) and is also in Phase II for various HER2-positive solid tumors. Additionally, the company is advancing KN019, a CTLA-4-based immunosuppressant fusion protein in Phase II clinical trials, which holds potential for diverse applications in autoimmune conditions and immune disorders arising from cancer treatments. The pipeline also features KN035, an injectable PD-L1 inhibitor that has successfully concluded pivotal Phase II clinical trials for solid tumors exhibiting deficient mismatch repair/microsatellite instability-high characteristics and is now in pivotal Phase III trials for biliary tract cancer. Finally, KN052, an innovative bispecific antibody targeting both PD-L1 and OX40, is in Phase Ia/Ib clinical development for the treatment of advanced solid tumors. Established in 2008, Alphamab Oncology's headquarters are located in Suzhou, People's Republic of China.
Biotechnology
Apollo Therapeutics is a biopharmaceutical company with headquarters located in Cambridge, United Kingdom, alongside offices in Boston, Massachusetts. The company advances breakthrough science to build a portfolio of innovative therapeutics.
Similar biotech company
Exelixis, Inc. is a biotechnology firm primarily focused on addressing oncology, dedicated to the discovery, development, and commercialization of innovative therapeutic agents for cancer treatment within the United States. The company markets several key medications. Its product portfolio includes CABOMETYX tablets, prescribed for patients with advanced renal cell carcinoma who have previously undergone anti-angiogenic therapy, and COMETRIQ capsules, utilized in the management of progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ are derived from cabozantinib, a potent inhibitor targeting multiple tyrosine kinases, notably MET, AXL, RET, and VEGF receptors. Additionally, Exelixis provides COTELLIC, an MEK inhibitor employed as part of a combination regimen for advanced melanoma. In Japan, it offers MINNEBRO, an oral, non-steroidal selective blocker of the mineralocorticoid receptor, indicated for the treatment of hypertension. Its development pipeline features several promising candidates. These include XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases implicated in cancer growth and dissemination; XB002, an antibody-drug conjugate comprising a human monoclonal antibody against tissue factor (TF), currently being evaluated for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for advanced or metastatic solid tumors. Exelixis maintains a wide array of research collaborations and licensing agreements with numerous partners, such as Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. The company, originally known as Exelixis Pharmaceuticals, Inc., adopted its current name, Exelixis, Inc., in February 2000. Established in 1994, its corporate headquarters are situated in Alameda, California.
Biotechnology
DeuterOncology is a clinical-stage drug development company that designs and develops deuterated MET kinase inhibitors as targeted therapies for lung cancer and other advanced solid tumors. Its lead product, DO-2, is a selective, brain-penetrant MET kinase inhibitor intended to improve tolerability and reduce toxicity compared to existing treatments.
Biotechnology
Alloplex Biotherapeutics, Inc. is a privately owned clinical-stage cellular therapeutics company with headquarters and laboratories located in Woburn, Massachusetts, developing robust platforms for treating cancer.
Biotechnology
Apmonia Therapeutics is a biotechnology company headquartered in Reims, France, committed to developing innovative therapeutic strategies for multiple types of cancer. Operating from its headquarters on Esplanade Roland, the firm advances oncology-focused drug candidates to target tumor progression. It is an active participant in the French biotech and life sciences ecosystem.
Similar biotech company
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Apollomics Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Apollomics Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →